April 17 (Reuters) - The U.S. Food and Drug Administration website showed that most doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarter of this year due to increased demand. (Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
737.2 USD | +0.50% | +0.80% | +26.47% |
Apr. 29 | Equity Markets Rise With Key Earnings, Fed Decision in Focus | MT |
Apr. 29 | US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.47% | 664B | |
+25.70% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.42% | 234B | |
+4.71% | 199B | |
-10.10% | 196B | |
-4.04% | 148B | |
-10.94% | 145B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says